Karma Oncology Ltd. is a specialized oncology clinical development company, working for the pharmaceutical and biotechnology industries globally. From the preparation of clinical development plans through design, set up, monitoring, management and reporting of clinical trials, Karma Oncology provides a bespoke service.
Individual Services or Full Service Global CRO Capabilities.
Novel Approaches to Save Sponsors Time and Money.
Adherence to Sponsor Timelines.
Lowest Turnover Rate in the Industry, <5% for CRAs, CTAs and Project Managers.
The Karma Oncology team is experienced in managing oncology trials in many different tumour types and using different therapeutic approaches.
The founder of the company, Dr Williams, has 30 years clinical research experience and has worked in both the pharmaceutical and CRO industries during her career. She has a BSc (Hons) in biology and P...
Our CPMs have a wealth of experience managing oncology clinical trials. Educated to degree/higher degree level or with nursing/midwifery backgrounds. Excellent communication and organisational skills....
CRAs are all ‘career’ CRAs, ie they have committed and are not looking for a step up the corporate ladder. CRAs, all mature, come from a variety of backgrounds including oncology research ...
Our CTAs are all educated to degree level....
Karma Oncology will attend a number of events. If you wish to set up a meeting with us to hear more about our unique organisation and how our expertise in delivering oncology clinical trials can support your oncology portfolio, please contact;
DIA Meeting – 24-28th June 2018, Boston, MA, USAEACR25 Meeting – 30th June-3rd July 2018, AmsterdamBioPharm America – 5-6th September 2018, Boston, MA, USAECCO 2018 Meeting – 7th-9th September 2018, ViennaBIO Japan – 10th-12th October, JapanESMO 2018 Meeting – 19th-23rd October 2018, MunichNCRI Cancer Conference – 4th-6th Nov 2018, Glasgow, UKBIO-Europe 2018 5th-7th November 2018, Copenhagen & Malmö (Skåne) ASH 2018 Meeting – Dec 1st-4th, 2018, San DiegoAACR 2019 – 30 March – 3 April 2019, AtlantaESMO 2019 Meeting – 27th Sept-1st Oct 2019, BarcelonaAACR 2020 Meeting – 25th-29th April 2020, San DiegoAACR 2021 Meeting – 10th-14th April 2021, Washington, DCAACR 2022 Meeting – 9th-13th April 2022, New Orleans
Karma Oncology will be attending EACR25 on June 30th to 3rd July in Amsterdam. To arrange a meeting and learn more about our unique, oncology specialized clinical research company, and how we can support your oncology portfolio please contact Dr Kara Kennedy – Kara.Kennedy@karmaoncology.com. Our skilled team design clinical development plans & study protocols, perform clinical trial start-up & execution and reporting. With a flexible, competitive approach in all aspects of our business, we are committed to delivering successful, high quality trials within sponsor timelines.
Karma Oncology was awarded the French Research Tax Credit approval in 2017. This approval will help our existing and future clients in France to benefit from this R&D tax credit. Since Karma Oncology is listed as an “approved organization”, the French ministry will allow for significant refunds by any French R&D company on their spending on Karma Oncology services. The research tax credit is either deducted from annual corporate tax or reimbursed and is calculated based on the amount (“volume”) of R&D expenditure by the company in France.